Fluxion Will Use $6.9M in VC Cash to Develop, Market Microfluidic Platforms | GenomeWeb
Fluxion Biosciences announced earlier this month that it has secured $6.9 million in a second round of venture capital and angel funding to help it hire more staff and to develop and commercialize three technology platforms.
They are the BioFlux 100 and 200 microfluidic platforms, which can be used for biofilm analysis and cellular-adhesion analysis, respectively, and the IonFlux automated-electrophysiology platform, which is intended for ion channel studies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.